Genentech's giredestrant cuts breast cancer recurrence risk by 30%

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced that its investigational drug giredestrant reduced the risk of invasive disease recurrence or death by 30% in patients with estrogen receptor-positive, early-stage breast cancer, according to results from the Phase III lidERA study.

The interim analysis showed giredestrant achieved superior invasive disease-free survival compared to standard-of-care endocrine therapy, with a hazard ratio of 0.70 and a 95% confidence interval of 0.57-0.87. At three years, 92.4% of patients receiving giredestrant remained alive and free of invasive disease versus 89.6% in the standard treatment group.

The study enrolled over 4,100 patients with medium- or high-risk stage I-III estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. Giredestrant also demonstrated a 31% risk reduction in distant recurrence-free interval, another key secondary endpoint.

"After almost 25 years, a new medicine – giredestrant – has demonstrated superiority over existing endocrine therapies in the curative setting," said Aditya Bardia, director of the breast oncology program at UCLA and the study's principal investigator.

Estrogen receptor-positive breast cancer accounts for approximately 70% of breast cancer cases, with up to one-third of patients experiencing recurrence despite adjuvant endocrine therapy treatment. Giredestrant is an oral selective estrogen receptor degrader designed to block estrogen from binding to estrogen receptors and trigger their breakdown.

The results will be presented at the 2025 San Antonio Breast Cancer Symposium. Overall survival data were described as immature at the time of analysis, though the company noted a positive trend. Adverse events were reported as manageable and consistent with the drug's known safety profile.

You May Also Be Interested In

• Apple suing OpenAI over alleged misappropriation of trade secrets
• Ideal Power (IPWR) files $75M mixed shelf
• Healthcare Triangle, Inc (HCTI) files for 28M share offering by selling stockholders